L3VLUP
ProSign in

ARWR · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARWRJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARWR
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterARWRJNJ
Q3 20204 holders, $221m30 holders, $26.2bn
Q4 20205 holders, $372m32 holders, $26.6bn
Q1 20215 holders, $336m31 holders, $25.3bn
Q2 20216 holders, $253m37 holders, $25.6bn
Q3 20215 holders, $133m40 holders, $24.1bn
Q4 20213 holders, $249m33 holders, $25.2bn
Q1 20225 holders, $161m35 holders, $28.2bn
Q2 20223 holders, $122m33 holders, $26.9bn
Q3 20223 holders, $118m36 holders, $25.4bn
Q4 20222 holders, $121m35 holders, $27.6bn
Q1 20234 holders, $69m42 holders, $24.5bn
Q2 20234 holders, $67m38 holders, $25.0bn
Q3 20233 holders, $62m37 holders, $18.9bn
Q4 20234 holders, $87m31 holders, $19.0bn
Q1 20244 holders, $67m32 holders, $19.7bn
Q2 20244 holders, $61m35 holders, $20.4bn
Q3 20243 holders, $29m28 holders, $22.3bn
Q4 20243 holders, $40m37 holders, $20.4bn
Q1 20252 holders, $7.4m32 holders, $20.5bn
Q2 20255 holders, $56m31 holders, $18.4bn
Q3 202510 holders, $232m32 holders, $23.7bn
Q4 20256 holders, $275m29 holders, $27.8bn
Q1 20268 holders, $257m34 holders, $35.6bn
Q2 20269 holders, $969m33 holders, $39.1bn
ARWR

Arrowhead Pharmaceuticals In

Holders
9
Reported value
$969m
Buyers
16
Sellers
16

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARWR (3)

Artisan Partners LP, Polen Capital Management LLC, Renaissance Technologies LLC

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →